Trialszenagamtidesemaglutidenovo nordiskobesity

Novo starts Phase 3 AMAZE 7 comparing zenagamtide with semaglutide in obesity

The recruiting trial pits once-weekly subcutaneous zenagamtide against once-weekly semaglutide for weight loss in adults with excess body weight.

By Priya Raman · Science Reporter

Sep 28 08:00 ETSource: ClinicalTrials.gov

The wire

01ClinicalTrials.gov entry NCT07668414, a Novo Nordisk-sponsored Phase 3 study, began Sept. 22, 2026 and is recruiting participants with overweight or obesity.
02A head-to-head design against semaglutide signals Novo intends to position zenagamtide on efficacy rather than against placebo, relevant to prescribers tracking the incretin pipeline.
03The registration lists no enrolment target, dose or primary endpoint details, and no results are available; readers should treat it as trial-design news only.

From the source

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414 · PHASE3 · RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Overweight, Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07668414